Supporter News: BMS AFib Study

Enrolling Now: Atrial Fibrillation Study

An investigational research study, sponsored by Bristol-Myers Squibb, is currently open for the enrollment of patients with paroxysmal atrial fibrillation which is NOT under control. The purpose of the study,  CV205-005, is to compare the safety, tolerability, and effectiveness of an investigational medication vs placebo, to reduce AFib burden. Individuals who are eligible to enroll in this 87 day study, will receive 1 of 4 dosing regimens that includes 3 active and 1 placebo, in a 3:1 ratio. The study procedures are conducted on an outpatient basis. Study sites are open in the United States and Canada.

Subjects who qualify would discontinue their current anti-arrhythmic medication and the study will evaluate the safety and effectiveness of the investigational medication or placebo throughout the duration of their participation.

For more information, or to find a study site, visit, or